Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.